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ABSTRACT
Telomeres, the physical ends of eukaryotes
chromosomes are transcribed into telomeric
repeat containing RNA (TERRA), a large non-coding
RNA of unknown function, which forms an integral
part of telomeric heterochromatin. TERRA mol-
ecules resemble in sequence the telomeric DNA
substrate as they contain 50-UUAGGG-30 repeats
near their 30-end which are complementary to the
template sequence of telomerase RNA. Here we
demonstrate that endogenous TERRA is bound to
human telomerase in cell extracts. Using in vitro
reconstituted telomerase and synthetic TERRA mol-
ecules we demonstrate that the 50-UUAGGG-30
repeats of TERRA base pair with the RNA template
of the telomerase RNA moiety (TR). In addition
TERRA contacts the telomerase reverse transcript-
ase (TERT) protein subunit independently of hTR.
In vitro studies further demonstrate that TERRA is
not used as a telomerase substrate. Instead, TERRA
acts as a potent competitive inhibitor for telomeric
DNA in addition to exerting an uncompetitive mode
of inhibition. Our data identify TERRA as a telomer-
ase ligand and natural direct inhibitor of human
telomerase. Telomerase regulation by the telomere
substrate may be mediated via its transcription.
INTRODUCTION
Telomeres protect chromosome ends from DNA repair
activities that reseal chromosome internal DNA breaks
that occur during DNA damage (1). Telomeric DNA
shortens with every round of semiconservative DNA rep-
lication due to the end replication problem and nucleolytic
processing. Short telomeres induce cellular senescence.
The telomerase enzyme can solve the end replication
problem re-extending telomere 30-ends by reverse
transcribing the template region of its tightly associated
RNA moiety into telomeric repeats (2,3). The regulation
of telomerase at chromosome ends is not very well under-
stood and subject of intensive investigations in several
laboratories.
Telomeres establish a heterochromatic state at chromo-
some ends which is characterized by the presence of
trimethylated lysines at positions 9 in histone H3 and 20
in histone H4, histone hypoacetylation, the accumulation
of several isoforms of heterochromatin protein 1 and
hypermethylation of cytosines in CpG-dinucleotides
present in subtelomeric regions (4,5). Recent analysis has
identiﬁed telomeric repeat containing RNA (TERRA), a
large non-coding (nc) RNA in animals and fungi, which
forms an integral component of telomeric heterochroma-
tin (6–9).
Several ﬁndings suggest that TERRA may regulate tel-
omerase at chromosome ends. First, in human cells
TERRA is displaced or degraded at telomeres by NMD
factors which physically interact with the telomeric chro-
matin (6). Among these factors, EST1A/SMG6 was also
identiﬁed through its sequence similarity with the
Saccharomyces cerevisiae telomerase associated protein
Est1 (10,11). Moreover, like yeast Est1, human EST1A/
SMG6 physically interacts with telomerase (10–12). The
association of EST1A/SMG6 with telomerase is compat-
ible with a role in telomerase regulation but its eﬀects on
TERRA displacement at telomeres suggest that EST1A/
SMG6 may regulate telomerase via TERRA. Second, the
TERRA mimicking RNA oligonucleotide (UUAGGG)3
inhibits telomerase activity in vitro as determined in the
TRAP assay (7) and it has been proposed that telomerase
may be regulated by TERRA in a telomere length depend-
ent manner (7). Third, genetic experiments in S. cerevisiae
provide evidence that TERRA regulates telomerase
in vivo. In the rat1-1 mutant background in which the
function of the 50–30 exonuclease Rat1p is reduced,
TERRA is up-regulated and telomeres are shorter than
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in wild-type cells due to impairment with telomerase-
mediated telomere elongation (8). Overexpression of
RNaseH reduced TERRA levels and could overcome the
short telomere phenotype indicating that a DNA/TERRA
hybrid was responsible for the eﬀect. Further support for
the role of TERRA in inhibiting telomerase in vivo stems
from an observation that forced telomere transcription
(through the use of the strong Gal-promoter) leads to
telomere shortening of the transcribed telomere in cis (13).
Here, we provide evidence that telomerase physically
interacts with TERRA in vivo. We identify the molecular
interaction sites of TERRA and telomerase, and deter-
mine the mode of telomerase inhibition in direct telomer-
ase assays. Our results substantiate the notion that
TERRA acts as a natural ligand and inhibitor of telomer-
ase in vivo.
MATERIALS AND METHODS
Immunoprecipitation from cell extracts and RNA
detection
293T cells were transfected with 4 mg of plasmid DNA per
well of a 6-well plate using Lipofectamine 2000 as recom-
mended by the supplier (Invitrogen). After 24 h
post-transfection, the cells of two wells were transferred
in a 150 cm2 dish. Post-transfection nuclear extracts (48 h)
were prepared as follows: cells were collected and resus-
pended in 750 ml buﬀer A [10mM HEPES pH 7.5, 10mM
KCl, 0.1mM EGTA, 0.1mM EDTA, 1mMDTT, 0.5mM
PMSF and protease inhibitor cocktail (Roche)] and
incubated on ice for 15min. Cold NP40 was added to a
ﬁnal concentration of 0.6%, samples were vortexed 10 s
and centrifuged for 1min at 16 100g. The supernatant was
removed and the nuclear pellet resuspended in 500 ml
buﬀer B (20mM HEPES pH 7.5, 400mM NaCl, 1mM
EGTA, 1mM EDTA, 1mM DTT, 0.5mM PMSF and
protease inhibitor cocktail (from Roche), and gently
shaken for 15min at 4C. After centrifugation at 16 100g
for 10min, the supernatant was diluted twice with
buﬀer C (1.2% NP40, 20% glycerol). Total protein con-
centration was determined with the Bradford assay and
the same amount of total nuclear extract was used per
immunoprecipitation. Extract was pre-cleared for 1 h at
4C with sepharose protein G beads (GE Healthcare).
Pre-cleared extract (300ml) (corresponding 6 106
cells) was incubated with either 2 mg of a-tubulin
[(TU-02) sc-8035 from Santa Cruz], a-hnRNPA1
[(4B10) sc-32301 from Santa Cruz] or a-Myc (9B11
from NEB) antibodies for 1 h at 4C. Fifteen microliter
of a 50% slurry of protein G beads was added and
incubated over-night at 4C. Beads were recovered by
spinning 1min at 1500g) and washed ﬁve times with
buﬀer B containing NP40 0.6%. The beads were
re-suspended in 100 ml buﬀer B containing 0.6% NP40
and 10% glycerol. Protein fractions were loaded on
4–20% gradient Tris–HCl PAGE gold gels (Lonza).
After transfer and western blotting, the signals were
measured using the ChemiGlow substrate (Wytec) on a
FluorChemTM 8900 machine (Alpha Innotech). RNA
was extracted with the RNeasy mini kit (Qiagen) for
analysis by reverse transcription (RT)-PCR. For detection
of TERRA association with endogenous telomerase the
protocol was scaled up 5-fold (30 106 cells per IP).
Anti-hTERT antibodies raised in rabbits (r819) and
pre-immune serum (negative control) were pre-incubated
with protein A beads (1: 1 volume) and washed exten-
sively. Twenty microliter of 50 % slurry was used per IP.
Anti-hTERT serum
Serum r819 was obtained from immunization of a rabbit
with a His6-tagged C-terminal fragment of hTERT (99 last
amino acids). The His6-hTERT C-terminal fragment was
overexpressed in Escherichia coli and puriﬁed on
Ni–agarose beads under denaturing conditions.
Telomerase reconstitution in rabbit reticulocyte lysates
and immunoprecipitation
Experiments were done similarly as described (12). Brieﬂy,
Flag-hTERT and Myc-hTERT were translated in the
presence of [35S]-methionine in the rabbit reticulocyte
lysate (RRL) TnT quick-coupled transcription/translation
system following the instructions of the supplier
(Promega). hTR was transcribed with the Ribomax
large-scale RNA production system-T7 kit (Promega).
After in vitro transcription, DNA templates were
removed by DNase I digestion and the RNA samples
were extracted with phenol:chloroform (1 : 1) and
precipitated with ethanol. Analysis of the RNA samples
by gel electrophoresis conﬁrmed their correct length and
intactness. For telomerase reconstitution, 80 ng of hTR
per microliter of RRL was incubated for 90min at 30C
(14). Immunoprecipitation was done as described (12).
For oligonucleotide-binding experiments, 1 ml of
[32P]-labeled oligonucleotide (0.1 pmol/ml) and 1 mg
E. coli tRNA were added to 85 ml of IPIII buﬀer [20mM
HEPES pH 7.5, 150mM NaCl, 10% glycerol, 0.2%
Tween 20, 0.02U/ml SUPERase-in (Ambion) and
protease cocktail inhibitor (EDTA-free, Roche)] and
12.5 ml of the RRL-mix and incubated 1 h at 25C. After
immunoprecipitation with a-Myc antibodies (9B11 from
NEB), beads were washed ﬁve times in 500 ml IPIII buﬀer.
Samples were loaded on 4–20% gradient Tris–HCl PAGE
gold gels (Lonza). Gels were dried. [35S]-labeled proteins
and [32P]-labeled oligonucleotides were detected and
quantiﬁed on a PhosphoImager. [32P]-labeled oligonucleo-
tides could be distinguished from [35S]-labeled proteins by
shielding the lower energy [35S]-derived b-rays with a sheet
of plastic.
RT-PCR
RT was performed with Superscript III (Invitrogen) using
speciﬁc primers for hTR (50-GTCCCACAGCTCAGGGA
ACT-30) and TERRA [50-(CCCTAA)5-30]. PCR was per-
formed with Phusion enzyme (Finnzymes) and hTR
primers fw790 and R3c (15) or the TERRA XpYp
subtelomeric primers (6). PCR was performed on serial
dilutions of the cDNA to ensure that the obtained signal
was in correlation with the amount of cDNA. The cDNA
was ﬁrst denatured for 30 s at 98C followed by 40 PCR
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cycles involving 5 s at 98C, 10 s at 55C and 20 s at 72C.
Cycling was followed by a 5min incubation at 72C.
For detection of TERRA association with endogenous
telomerase, RT and PCR primers were as above for hTR
and TERRA. For U2 the RT primer was 50- GCACCGTT
CCTGGAGGTACTG-30, the forward PCR primer 50-GG
CTAAGATCAAGTGTAGTATCTGTTC-30 and the
reverse PCR primer 50-GCTCCTATTCCATCTCCCTG
CTC-30. One-third of the cDNA was used for the XpYp
qPCR, and 1/20 for hTR and U2 qPCRs. The qPCR was
carried out in the 7900HT fast real time PCR system
(Applied Biosystem) and the power sybr green kit
(Applied Biosystem) was used for detection of products.
The cDNA was ﬁrst denatured for 10min at 95C
followed by 45 PCR cycles involving 15 s at 95C and
1min at 60C.
hTR mutants
hTR template mutants were generated and transcribed by
T7 RNA polymerase as described earlier (15). The hTR
wild-type template sequence is: 30-CAAUCCCAAUC-50;
hTR comp template sequence: 30-CUUAGGGUUAG-50;
hTR C2 template sequence: 30-CAACAAAAACA-50.
Direct telomerase activity assay and Telospot
Telomerase assays were performed as described (16) for
45min at 30C. For the Telospot assays, the reactions
were done in 20 ml at 30C for 45min or for 30min in
Figure 3. After the reaction, samples were treated with
200 ng RNaseA for 30min at 37C. Reaction mixture
(0.5 ml) was spotted in triplicate on a Hybond N+
membrane. The membrane was incubated with a
randomly labeled TTAGGG speciﬁc probe and quantiﬁed
as described (16). Signals were quantiﬁed by Image Quant.
For IC50 calculations, the GraphPad Prism software was
used.
RESULTS
TERRA is bound to human telomerase in nuclear extracts
TERRA has been proposed to directly regulate telomer-
ase, suggesting a physical interaction between these
macromolecules. In order to test this hypothesis we tran-
siently transfected 293T cells with plasmids that speciﬁed
the expression of Myc-tagged human telomerase reverse
transcriptase (hTERT) under control of the CMV
promoter and hTR under control of the U1-promoter.
Nuclear extracts were prepared 48 h post-transfection
and telomerase was immunoprecipitated via the Myc-tag
(Figure 1A). HnRNPA1 and tubulin were also
immunoprecipitated for control purposes. Presence of
TERRA and hTR in the fractions was assessed by
RT-PCR (Figure 1B). This analysis revealed that
TERRA and hTR were co-immunoprecipitated with
tagged hTERT. No RT-PCR signals were obtained in
the IP-fractions from mock extracts or with antibodies
against tubulin. Immunoprecipitation of hnRNPA1 also
revealed association of TERRA and hTR with this
protein. HnRNPA1 is a known ligand of telomerase
(17–19) and a large fraction of TERRA is also associated
with hnRNPA1 (Figure 1; S.R. and J.L., unpublished).
We could also detect an interaction between endogenous
telomerase and TERRA. For this, endogenous hTERT
was immunoprecipitated from non-transfected 293T
nuclear extracts using rabbit anti-hTERT antibody
(r819). Pre-immune serum was used as a negative
control. Presence of hTR, TERRA and U2 snRNA
(negative control) were measured by RT-qPCR. Control
experiments with Myc-hTERT extracts indicated that r819
antibody pulled down hTERT 6 less eﬃciently than the
anti-Myc antibody. Nevertheless, the hTERT serum
pulled down approximately two times more TERRA
than the pre-immune serum (Ct value r819: 30.68±0.22;
Ct value pre-immune: 31.47±0.11; three independent ex-
periments; t-test P=0.046) and a similar diﬀerence was
obtained for hTR (Ct value r819: 16.30±0.58; Ct value
pre-immune: 17.89±0.30; P=0.012). On the other hand,
U2 snRNA was not enriched via the hTERT antibody
(Ct value r819: 12.40±0.42; Ct value pre-immune:
12.29±0.30; P=0.81).
TERRA binds the template sequence of hTR and the
TERT polypeptide
In order to characterize the molecular interaction between
TERRA and telomerase, we expressed and reconstituted
wild-type and mutant telomerases in vitro. HTR was
transcribed in vitro from plasmids by run-oﬀ transcription
with T7 RNA polymerase and combined with TERT that
was expressed in RRL in presence of [35S]-methionine.
-
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Figure 1. Endogenous TERRA is bound to telomerase. (A)
Immunoprecipitation and analysis by western blotting.
Immunoprecipitation was done with antibodies against tubulin (Tub),
hnRNPA1 (A1) and the Myc-epitope. Western blots were probed with
a-hTERT antibody (upper) and a-hnRNPA1 antibody (lower). I, input;
IP, protein extracted from the beads after the immunoprecipitation; B,
beads only control. One-ﬁfteenth of the input and 1/10 of the
immunoprecipitates was loaded. (B) RT-PCR for XpYp TERRA and
hTR. RNA extracted from input (I) or from the beads after
immunoprecipitation was analyzed. Immunoprecipitations were done
with nuclear extracts from 293T cells transfected either with
pBS-U1-hTR and pCDNA6MychTERT or with empty vectors. RT:
negative control in which no RT was added to the reaction.
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50-32P-labeled TERRA-sequence containing RNA and
DNA oligonucleotides were added to telomerase in
presence of excess of tRNA competitor. After 1 h at
25C, telomerase was immunopuriﬁed via the Myc-tag.
Fractions were separated by SDS–PAGE and exposed to
a PhosphorImager in order to visualize 35S-labeled
Myc-hTERT and 32P-labeled RNA and DNA
(Figure 2). This analysis revealed that (50-UUAGGG-30)3
associated readily with hTERT in presence of wild-type
hTR (Figure 2A and C). When telomerase was
reconstituted with mutant hTR containing mutant
template sequences (hTR comp and hTR C2; ‘Materials
and Methods’ section) and immunopuriﬁed, association
with telomerase was reduced but not abolished, to levels
that were observed with hTERT alone. These results
indicate that (50-UUAGGG-30)3 binds to the telomerase
RNA template sequence through base pair interaction. In
addition since binding was only reduced but not abolished
in the absence of hTR or with the template mutants, (50-U
UAGGG-30)3 is also bound by the hTERT polypeptide.
We also assessed whether the binding of RNA to the hTR
comp mutant template could be rescued by introducing
complementary mutations into the RNA oligonucleotide
(Figure 2A, right panel). Indeed 50-(AAUCCC)3-30 being
complementary to the mutated template sequence hTR
comp was readily binding to hTERT/hTR comp but not
to hTERT or hTERT/hTR wt. As opposed to 50-(UUAG
GG)3-3
0, 50-(AAUCCC)3-30 did not bind signiﬁcantly to
hTERT which supports the speciﬁc recognition of
TERRA by hTERT. The DNA 50-(TTAGGG)3-30 oligo-
nucleotide behaved similarly in this assay as 50-(UUAG
GG)3-3
0 making interactions with the RNA template
and hTERT, though the binding aﬃnity was lower. No
binding was observed between telomerase and rA18 or
dA18 as expected.
A fraction (8%) of TERRA is polyadenylated (7,20)
whereas the majority of TERRA ends with 50-UUAGGG
-30-repeats or a permutation thereof (A. Porro and J.L.,
unpublished). We therefore wanted to test if association
depended on the presence of 50-UUAGGG-30 at the 30-end
(Figure 2B and C, Supplementary Figure S1). The
telomerase binding assay was repeated with 50-(UUA
GGG)3A6-3
0, 50-(TTAGGG)3A6-30 RNA and DNA oligo-
nucleotides. Telomerase bound to telomeric RNA and
DNA oligonucleotides independently of the presence of
a terminal oligo A-tail and with a similar eﬃciency. In
addition, the interactions with RNA and DNA oligo-
nucleotides involved both, base pairing with the RNA
template sequence and interactions with the hTERT poly-
peptide. This indicates that telomerase can also bind to
internal telomeric RNA and DNA repeats.
TERRA is a potent telomerase inhibitor
The above analysis revealed a similar binding behavior of
telomeric RNA and DNA to telomerase suggesting that
TERRA might compete for the binding of telomeric DNA
substrates. We therefore tested the eﬀects of various telo-
meric and non-telomeric RNA oligonucleotides on tel-
omerase activity in direct telomerase assays in vitro.
Telomerase activity was obtained from HEK293T cells
overexpressing hTERT and hTR [so-called
supertelomerase extracts (21)], and extension of telomeric
oligonucleotides was detected upon addition of telomeric
repeats onto telomeric DNA substrates (Figures 3–5).
Since direct telomerase assays do not involve PCR ampli-
ﬁcation as done in the TRAP assay (22), information on
telomerase processivity can be obtained (see below). In
Figure 3A, telomere oligonucleotide extension was
measured by Telospot. In this assay the reaction
products are spotted onto a nylon membrane and the
elongated DNA substrates are detected upon hybridiza-
tion with a radiolabeled DNA probe (16). Addition of
increasing amounts of 50-(UUAGGG)3-30 led to
complete inhibition of telomerase activity, with an
IC50 of 68±28nM (nine independent experiments;
Figure 3B).
In Figure 3C, telomere DNA extension was measured
upon incorporation of radiolabeled 32P-dGTP and the
products were separated on a sequencing gel. Also in
this assay, addition of increasing amounts of 50-(UUAG
GG)3-3
0 led to complete inhibition of telomerase activity,
whereas rA18 had no eﬀect. As published, addition of the
small molecule inhibitor BIBR1532 also inhibited telomer-
ase (23,24). However, the eﬀects of 50-(UUAGGG)3-30 and
BIBR1532 were strikingly diﬀerent. Whereas with 50-(UU
AGGG)3-3
0, the abundance of long and short products
disappeared simultaneously, BIBR1532 aﬀected mostly
accumulation of the longer extension products
(Figure 3C). Quantiﬁcation of the repeat addition
processivity of telomerase in presence of these two inhibi-
tors revealed that BIBR1532 reduced telomerase
processivity as reported previously (24) whereas 50-(UU
AGGG)3-3
0 reduced the overall activity with no eﬀects
on processivity (Figure 3D). The latter is typical for com-
petitive inhibitors.
Mode of telomerase inhibition by TERRA
As the substrate concentration increases in the assay
mixture, a purely competitive inhibitor would exhibit a
diminished, and ultimately unattainable, inhibition. We
tested the mode of inhibition by TERRA using the
Telospot assay, by titration of two diﬀerent DNA sub-
strates [TS: 50-AATCCGTCGAGCAGAGTT-30 and
50-ACTATC(TTAGGG)2-30] in presence of four diﬀerent
concentrations of inhibitor (Figure 4). The total DNA
oligonucleotide concentration was kept constant in the
reactions (648 nM) through addition of dA18 which is
not a substrate for telomerase (indicated on the top of
Figure 4A). The plot of telomerase activity as a function
of primer substrate concentration indicated that even at
highest primer concentration, presence of the 50-(UUAGG
G)3-3
0 inhibitor strongly reduced the maximal amount of
reaction product, indicating reduced maximal velocity
Vmax in presence of the TERRA-inhibitor (Figure 4B).
With 80 nM TERRA, the Vmax for the TS-primer
decreased 2.5-fold. The clear reduction of Vmax is not
compatible with a purely competitive inhibition of tel-
omerase by TERRA. The primer concentration at which
half-maximal velocity was observed (Km) also increased
with increasing concentration of inhibitor as expected
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Figure 2. TERRA base pairs with the hTR template and interacts with the catalytic subunit of telomerase hTERT. (A) Interaction with telomeric
RNA and DNA oligonucleotides. Top panel: [32P] 50-end labeled 50-(UUAGGG)3-30, 50-(AACUUU)3-30 or rA18 was incubated with in RRL
translated [35S] methionine-labeled Flag-hTERT or Myc-hTERT which were both previously incubated or not with full-length in vitro transcribed
wild-type hTR (hTR wt) or hTR bearing a template sequence that was complementary to the wild-type sequence (hTR comp) or a mutated template
region (hTR C2). After immunoprecipitation with a-Myc antibodies and ﬁve washes, samples were separated on 4–20% gradient protein gels. One
percent of the radiolabeled oligonucleotides and 8% of the radiolabeled proteins were loaded in the input, whereas 100% were loaded for the IP
fractions. [35S] and [32P] signals were revealed by analysis on a PhosphorImager. By placing a plastic ﬁlm between the gel and the PhosphorImager
screen, only the [32P] signal was detected (lower part). (A) Bottom panel: same experiment as in (A) top panel except that the experiment was done
with DNA instead of RNA oligonucleotides: (TTAGGG)3 and dA18. (B) Interaction with oligoA containing telomeric RNA and DNA oligonucleo-
tides. Top panel: [32P] 50-end labeled 50-(UUAGGG)3-30 and 50-(UUAGGG)3A6-30. Bottom panel: 50-(TTAGGG)3-30 and 50-(TTAGGG)3A6-30.
(C) Quantiﬁcation of oligonucleotides co-precipitated with Myc-hTERT based on the gels in panels (A) and (B) and one additional experiment.
The values were normalized by the immunoprecipitation eﬃciency of the individual polypeptides and background signals present in the lane
Flag-hTERT were subtracted from the values.
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Figure 3. TERRA inhibits telomerase activity without perturbing repeat addition processivity. (A) Telospot assay with 50-(TTAGGG)3-30 as a
substrate and serial titration of 50-(UUAGGG)3-30. Each reaction was done three times (rows) and spotted in triplicate. EDTA (25mM) was
used as a positive control for complete inhibition. (B) Determination of IC50. The graph shows the quantiﬁcation of the data obtained in (A).
The mean of the three spot intensities was used to calculate the IC50 by ﬁtting the data to a sigmoidal dose response curve. The indicated IC50 value
was calculated from nine independent experiments. (C) Direct telomerase activity assay in presence of 35 nM 50-biotinylated 50-(TTAGGG)3-30 primer
and dATP, dTTP and 32P-a-dGTP. Concentrations and identity of competitor oligonucleotides are indicated on the top. Reaction products were
puriﬁed via the biotin-tag with streptavidin containing magnetic beads and resolved on an 8% polyacylamide sequencing gel. B-10mer
(a 50-radiolabeled and 30-biotinylated 10-mer oligonucleotide) was used as recovery control and was added before DNA puriﬁcation. The
numbers on the left of the gel indicate the number of nucleotides added to the 30 end of the primer. (D) Eﬀects on repeat addition processivity.
Signal intensities for each telomeric repeat seen in (C) were measured, corrected for the number of radiolabeled nucleotides incorporated and then
plotted. Increased amounts of 50-(UUAGGG)3-30 resulted in lines with the same slopes indicating no change in repeat addition processivity.
However, increased amounts of BIBR1532 resulted in lines with steeper slopes indicating a decrease in processivity.
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for a competitive inhibitor. With 80 nM TERRA, the Km
for the TS-primer increased 4.3-fold from 16 to 69 nM. A
simple reaction scheme was assumed in which the inhibi-
tor (I) would be able to bind either to the free telomerase
enzyme (E) or the enzyme–substrate (ES) complex
(Figure 4C, right). Reaction constants for inhibitor
binding were calculated. The value of Ki was
4.7–6.7-fold smaller than K 0i, indicating a higher aﬃnity
of the inhibitor for the free enzyme than for the ES
complex. However, the calculated K 0i value indicated con-
siderable aﬃnity of 50-(UUAGGG)3-30 also for the ES
complex whereas a purely competitive inhibitor should
not be able to bind the ES complex at all. Overall, the
analysis indicates that the TERRA-oligonucleotides act
as mixed-type competitive inhibitors for the binding of
telomeric DNA.
Telomerase inhibition does not depend on sequence
identity at the TERRA 30-end
Although TERRA 30-ends have a preferred register, they
can end in all six circular permutations of the 50-UUAGG
G-30 sequence, in addition to the poly(A) tail that is
present at 8% of the TERRA 30-ends (A. Porro and
J.L., unpublished). We therefore tested if the sequence
identity at TERRA 30-ends inﬂuenced the ability to
inhibit telomerase (Figure 5A and C). Titration of the
permutated oligonucleotides showed potent inhibition
with all TERRA-sequences and IC50 values between 16
and 82 nM [IC50 values were obtained from the quantiﬁ-
cation of three independent Telospot assays (data not
shown)]. Presence of oligo A6 at the TERRA-
oligonucleotide 30-end did not diminish the inhibition
(IC50=8nM). The ability of TERRA oligonucleotides
to inhibit telomerase was also compared to the ability of
DNA oligonucleotides of the same sequence to compete
for telomere oligonucleotide extension (Figure 5B). In
these experiments, the substrate carried a biotin at the
50-end and was separated from the competing DNA
after the reaction. 50-(TTAGGG)3-30 (which is a substrate)
was a better competitor than 50-(TTAGGG)3A6-30 (which
is not a substrate). Strikingly, however, the DNA oligo-
nucleotides had IC50 values that were 1–2 orders of
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Figure 4. TERRA is a mixed-type inhibitor of telomerase activity. (A) Telospot assay with increasing amounts of inhibitor. Telomerase activity was
measured in presence of diﬀerent concentrations (0–648 nM) of the TS primer (50-AATCCGTCGAGCAGAGTT-30). The total DNA oligonucleotide
concentration was kept constant in each reaction through addition of dA18 (from 648 to 0 nM). rA18, (UUAGGG)3 and BIBR1532 were added as
indicated on the right side. Each reaction was spotted in triplicate. (B) Quantiﬁcation of telomerase activity from (A) as a function of TS primer in
presence of increasing amounts of (UUAGGG)3. (C) Table with kinetic constants for two diﬀerent primers and reaction constants for inhibitor
binding. A simple reaction scheme (right side) was assumed in which the inhibitor (I) would be able to bind either to the free telomerase enzyme (E)
or the enzyme–substrate (ES) complex. The constants were calculated from the following equations: n0=Vmax  [S]/(aKM+a0[S]); n0 is telomerase
activity measured on the membrane; [S] is the primer concentration; a=1+[I]/KI and a0=1+[I]/K0I; [I] is the inhibitor concentration. Results were
obtained from three independent experiments for the inhibition with 50-(UUAGGG)3-30 and from one experiment for the previously characterized
telomerase inhibitor BIBR1532.
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magnitude higher than the IC50 for TERRA-
oligonucleotides. These results underline the remarkable
aﬃnity of telomerase for TERRA-oligonucleotides,
which even exceed the aﬃnity for telomeric DNA.
DISCUSSION
In this article, we provide evidence that TERRA acts as a
negative regulator of telomerase. First, we demonstrate
that a fraction of endogenous TERRA is associated with
telomerase which was immunopuriﬁed from cellular
extracts. This result suggests that telomerase is associated
with telomerase in vivo. The colocalization of TERRA
with telomeric chromatin supports the notion that
TERRA and telomerase do associate in vivo. Second, we
demonstrate that telomerase binds in vitro to TERRA-
sequence containing RNA oligonucleotides. The
interactions between telomerase and TERRA-
oligonucleotides involve base pairing with the RNA
template and binding of TERRA by TERT.
Interestingly, telomerase binding can occur also to
internal 50-UUAGGG-30 repeats suggesting that a single
TERRA molecule may be able to bind and sequester
multiple telomerases.
Figure 5. Telomerase inhibition by TERRA is largely independent of its 30 end register. (A) Direct telomerase activity assays were performed with
35 nM of 50-biotinylated (TTAGGG)3-30 primer in the presence of dATP, dTTP and
32P-a-dGTP, and increasing concentrations (indicated in nM) of
rA18, 5
0-(UUAGGG)3-30 or permutations thereof as indicated, or 50-(UUAGGG)3A6-30. Reaction products were puriﬁed as in Figure 3B. B-15mer
(a 50-radiolabeled and 30-biotinylated 15-mer oligonucleotide) was used as recovery control and was added before DNA puriﬁcation. (B) Direct
telomerase activity assay as in (A) but in presence of DNA oligonucleotide inhibitors as indicated. (C) Relative IC50 values for permutations of
50-(UUAGGG)3-30 or 50-(UUAGGG)3A6- determined by the Telospot assay (three independent experiments; spotting data not shown).
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Third, we demonstrate in direct telomerase assays that
TERRA is a very potent inhibitor of human telomerase
in vitro. Indeed, TERRA-sequence containing RNA oligo-
nucleotides inhibit telomerase even more eﬀectively than
DNA oligonucleotides. This observation is in concordance
with a remarkable aﬃnity of telomerase for TERRA,
which exceeds that of telomeric DNA. The analysis of
repeat addition processivity supports competitive inhib-
ition of primer binding by TERRA. However, titration
experiments indicate a mixed-type inhibition suggestive
of more complex eﬀects of TERRA on telomerase than
mere competition with telomeric DNA substrates. It is
conceivable here that the identiﬁed telomerase RNA inde-
pendent TERT-TERRA interaction elicits allosteric inhib-
ition of telomerase activity. Notable in this respect is that
TERT contains a so-called anchor site which is thought to
bind the telomeric DNA substrate during substrate trans-
location, to prevent its dissociation (25–29). The anchor
site may allow addition of multiple telomeric repeats in a
processive manner. It is possible that TERRA binds to
this still ill-deﬁned anchor site in TERT but a separate
interaction site is also possible and might be more com-
patible with the observed mixed-type inhibition. Yet
another possibility is that the mixed-type inhibition can
be explained by the presumed dimeric state of human tel-
omerase, which has been supported in several studies
(15,30–32). For example, it seems conceivable that the
binding of TERRA to one telomerase subunit alters the
conformation of the other, leading to complete inhibition
of catalytic activity but perhaps not DNA primer binding.
Whatever the exact mechanism, our data strongly support
the notion that TERRA also acts as a natural ligand and
inhibitor of telomerase in vivo. We are not aware of other
published examples in which natural RNA ligands act as
direct regulators of enzymatic activity without being a
substrate.
Under which physiological conditions does TERRA
control telomerase? TERRA transcription may be
induced or repressed in a telomere autonomous fashion
upon telomere length changes or upon changes in telomer-
ic chromatin composition, in order to locally repress and/
or sequester telomerase. Several modes of telomerase-
sequestration by TERRA can be envisioned (Figure 6).
Upon transcription, TERRA may be released from the
telomere, and bind and inhibit telomere-proximal telomer-
ase molecules and prevent their access to the chromosomal
end [Figure 6; scenario (1)]. Alternatively or in addition, it
is conceivable that telomeric heterochromatin bound
TERRA binds and sequesters telomerase [Figure 6;
scenario (2)]. In this scenario, TERRA would retain tel-
omerase near the telomeric 30-end while inhibiting its
action. Finally, it is conceivable that TERRA binds to
telomeric chromatin bound telomerase and prevents it
from accessing the telomeric 30-end [Figure 6;
scenario (3)]. It will be important to develop methods to
regulate TERRA expression and measure telomerase as-
sociation with the telomere in order to decipher the mode
of TERRA action. It will also be interesting to ﬁnd out if
inhibition of telomerase by TERRA is regulated and can
be induced or reversed by telomere length regulators.
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